3 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 5 Phase 1, 5 Phase 2, 2 Not applicable, 1 Early Phase 1.
Follow Radiopharmaceuticals: new trials by email Literature Review of Radiopharmaceuticals trials Research Report on Radiopharmaceuticals
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma 161Tb-PSMA-1 (radiopharmaceutical) - Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Centre Leon Berard | 26 | 2026-11-01 | 2026-09-18 |
| A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC Radiopharmaceuticals - Prostate Cancer | Phase 1 / Phase 2 | Recruiting | C Ray Therapeutics | 90 | 2026-05-22 | 2026-05-29 |
| Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer 177Lu-PSMA-1 (radiopharmaceutical) - Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | Centre Leon Berard | 6 | 2023-11-09 | 2026-04-24 |
| Molecular Imaging Exploration of Ocular Angiogenic Activity and Evaluation of Its Interest in the Therapeutic Follow-up of Patients With AMD (Age-related Macular Degeneration) radiopharmaceutical - Age Related Macular Degeneration | Not applicable | Unknown | Assistance Publique Hopitaux De Marseille | 20 | 2022-10-02 | 2023-02-08 |
| Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI) - Recurrent Thyroid Cancer | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 48 | 2021-03-17 | 2026-06-30 |
| PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy PET/CT, radioactive drug (tracer) - Cancer | Phase 1 / Phase 2 | Completed | Mayo Clinic | 6 | 2020-08-14 | 2023-09-13 |
| Tau Imaging With JNJ067 Radiopharmaceuticals - Alzheimer Disease, Mild Cognitive Impairment | Early Phase 1 | Completed | University of California, Berkeley | 18 | 2019-06-18 | 2022-08-31 |
| PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents radiopharmaceutical (Flotegatide (18F) or RGD (68Ga) - Advanced Head and Neck Carcinoma, Advanced Non-small Cell Lung Carcinoma | Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 1 | 2015-03-20 | 2022-07-19 |
| An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours Lu-DOTA-TATE - Neuroendocrine Carcinoma | Phase 2 | Active not recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 66 | 2014-07-01 | 2026-10-05 |
| PET/CT Evaluation of Treatment Response in Breast Cancer Radiopharmaceutical Administration [18F]-FDG, Radiopharmaceutical: [18F]-FLT - Breast Cancer | Not applicable | Terminated | Vanderbilt-Ingram Cancer Center | 50 | 2010-10-01 | 2017-07-02 |
Clear-cell metastatic renal cell carcinoma (2) · Alzheimer Disease (1) · Breast Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Cognitive Dysfunction (1) · Macular Degeneration (1) · Neoplasms (1) · Prostatic Neoplasms (1) · Supranuclear Palsy, Progressive (1) · Thyroid Neoplasms (1)
Centre Leon Berard (2) · Assistance Publique - Hôpitaux de Paris (1) · Assistance Publique Hopitaux De Marseille (1) · C Ray Therapeutics (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Mayo Clinic (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of California, Berkeley (1) · Vanderbilt-Ingram Cancer Center (1)
France (4) · United States (4) · Canada (1) · China (1)
A. Bapsi Chakravarthy, MD (1) · Dingwei Ye, MD, PhD (1) · Emilie Garrido Pradalie (1) · Harry Quon, MD (1) · John Bois, MD (1) · Nianzeng Xing, MD, PhD (1) · Yan Wu, MD (1)
2014 (1), 2019 (1), R01CA240779 (1)